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Abstract Both Alzheimer’s disease (AD), the most
common form of dementia, and type-2 diabetes mellitus
(T2DM), a disease associated with metabolic syndrome
(MetS), affect a great number of the world population and
both have increased prevalence with age. Recently, many
studies demonstrated that pre-diabetes, MetS, and T2DM
are risk factors in the development of AD and have many
common mechanisms. The main focus of studies is the
insulin resistance outcome found both in MetS as well as
in brains of AD subjects. However, oxidative stress (OS)-
related mechanisms, which are well known to be involved
in AD, including mitochondrial dysfunction, elevated iron
concentration, reactive oxygen species (ROS), and stress-
related enzyme or proteins (e.g. heme oxygenase-1,
transferrin, etc.), have not been elucidated in MetS or
T2DM brains although OS and iron are involved in the
degeneration of the pancreatic islet b cells. Therefore, this
review sets to cover the current literature regarding OS
and iron in MetS and T2DM and the similarities to
mechanisms in AD both in human subjects as well as in
animal models.
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Introduction
Type 2 diabetes mellitus (T2DM) is one of the most
important and prevalent chronic diseases. It currently
affects 250 million people worldwide, with 6 million new
cases reported each year (Cole et al. 2007). This prevalence
rises with age from 12% in people aged 65–70 to 15% in
people over age 80 (Wild et al. 2004). T2DM is a systemic
disease that can damage any organ in the body (Campbell
2009). Resembling diabetes, cognitive dysfunction, espe-
cially Alzheimer’s disease (AD), represents another serious
problem and is rising in prevalence worldwide, especially
among the elderly (Alzheimer’s 2010). Early onset of
T2DM, poor glycemic control and the presence of micro-
and macrovascular disease may interact to produce early
cognitive deficits (Awad et al. 2004; Ronnemaa et al. 2008,
2009). Several studies have reported a high risk of AD in
patients with T2DM (Ott et al. 1996, 1999; Leibson et al.
1997; Hassing et al. 2004a; Whitmer 2007). In addition, the
co-morbid hypertension and overweight were found to be
linked to risk of dementia (Hassing et al. 2004b, 2009;
Luchsinger and Gustafson 2009; Whitmer et al. 2008).
Many studies suggest that the risk of cognitive decline
and neurodegeneration is increased not only in T2DM, but
also in patients with pre-diabetes and metabolic syndrome
(MetS) (Luchsinger 2008). Individuals with pre-diabetes
are defined as those presenting with impaired fasting glu-
cose and/or impaired glucose tolerance (Yaffe et al. 2004),
which increases their risk of developing frank T2DM.
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These subjects already present with insulin resistance as a
pathophysiological mechanism that is often associated with
MetS (Yaffe et al. 2004; Luchsinger 2008). MetS, in turn,
is a cluster of interrelated cardiometabolic risk factors
including visceral obesity, dyslipidemia (elevated triglyc-
erides and/or low HDL-cholesterol), hypertension, dys-
glycemia (pre-diabetes or diabetes) (Spalding et al. 2009).
MetS was initially defined by the World Health Organi-
zation (WHO) in 1998 (Alberti and Zimmet 1998). The
prevalence of MetS varies depending on population. In
Europe as well as in the United States the prevalence
increases with age (Potenza and Mechanick 2009).
It has been suggested that an increase in the plasma
concentration of insulin while fasting was associated with
AD both in people with and without diabetes, which sug-
gests that insulin resistance, independent of diabetes, may
increase disease risk (Luchsinger et al. 2004; Kuusisto
et al. 1997). Consistent reductions in the regional cerebral
metabolic rate of glucose were also reported to exist in AD
brain (Fukuyama et al. 1994; Haense et al. 2009; Herholz
2003). However, this diminished glucose utilization was
not attributed to an insufficient supply of glucose to the
brain, but rather to diminished glucose breakdown in brain
tissue caused by a disturbance in the control of glucose
utilization at the level of insulin signal transduction (Hoyer
2004). Studies of hippocampal volume revealed a link
between insulin resistance and cognitive performance
(Rasgon et al. 2009). Indeed, insulin-receptors density is
up-regulated in AD showing an impairment of the insulin
signal transduction cascade similar to that seen in T2DM
(Fro¨lich et al. 1998). These results suggest that sporadic
AD is the ‘‘insulin-resistant brain state’’ (IRBS) (Hoyer
1998; Salkovic-Petrisic and Lackovic 2005). Insulin resis-
tance seems also to accelerate biological aging by fostering
the formation of advanced glycation end-products (AGE)
and, consequently, reactive oxygen species (ROS) (Smith
et al. 1995; Munch et al. 1997). The relation between
insulin and the metabolism of amyloid-b peptide (Ab) and
tau protein hyperphosphorylation in particular has been
receiving increasing attention over the past few years
(Gasparini and Xu 2003; Craft 2007, 2009).
However, the common mechanism involving iron and
oxidative stress (OS) is not yet a focus of attention. One
epidemiological study suggested the common etiology in
regard to induction of nitrosamine-OS in AD, T2DM as
well as in non-alcoholic steatohepatitis (de la Monte et al.
2009). Recently, a shift toward linking T2DM and AD is
becoming rather mainstream. But some years ago, it was
still controversial in regard to the involvement of vascular
components, such as AGE and OS in AD (Smith et al.
1996b). Therefore, in this review we attempt to cover the
current knowledge with regard to OS and iron involvement
both in AD and in T2DM.
Oxidative stress
Oxidative stress (OS) is characterized by a compromise
in the physiological removal of ROS and/or an increase
in their production that results from irreversible damage
to biomacromolecules. Oxidative damage of biomacro-
molecules has been described in the brains of AD
patients: (1) DNA and RNA oxidation is marked by
increased levels of 8-hydroxy-2-deoxyguanosine and
8-hydroxyguanosine (Nunomura et al. 1999, 2001); (2)
protein oxidation is marked by elevated levels of protein
carbonyl and nitration of tyrosine residues (Smith et al.
1996a); (3) lipid peroxidation is marked by high levels of
thiobarbituric acid-reactive substances (TBARS), mal-
ondialdehyde (MDA), 4-hydroxy-2-nonenal (HNE), and
isoprostanes and altered phospholipid composition (Sayre
et al. 1997); and (4) modification to sugars is marked by
increased glycation and glycoxidation (Smith et al.
1994b). The brain of AD patients, in particular the hip-
pocampus and amygdala, is hallmarked by increased OS
as demonstrated by the elevated activities of antioxidant
proteins, such as glutathione reductase, glutathione per-
oxidase, superoxide dismutase, and catalase (Perry et al.
2002).
In T2DM it is debated whether the involvement of
mitochondrial dysfunction may cause OS and cell
destruction in the pancreatic b-cells (Sivitz and Yorek
2010). It was reported recently, that redox-sensitive cellu-
lar signaling systems play an important role in the devel-
opment, progressive nature (remodeling), and damaging
effects on the b-cell within the islet of the pancreas
(Hayden and Tyagi 2002; Perez-Matute et al. 2009).
Iron accumulation in AD and T2DM
Iron is an essential component of proteins containing iron–
sulfur clusters, heme, and diiron-oxo metal centers that are
involved in important cellular processes like oxygen
transport, mitochondrial respiration, or DNA synthesis
(Rausch et al. 1988). Severe iron deficiency will cause
growth arrest and cell death. Iron is a transition metal that
can serve both as an electron donor and acceptor. In living
organisms, iron can be found in its reduced ferrous (Fe2?)
and its oxidized ferric (Fe3?) states. The same chemical
properties that make iron a highly versatile component in
numerous biological processes can cause toxicity if iron is
unshielded. Excess free iron is involved in the Fenton
redox reaction which catalyzes the conversion of ROS to
the highly reactive hydroxyl radical (OH) that will damage
DNA, proteins, and lipids. Because iron excess and defi-
ciency are equally detrimental for the cell, regulatory
mechanisms have evolved to maintain iron homeostasis
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both at the cellular and at the systemic levels (Hentze et al.
2004).
Iron progressively accumulates in the brain with age
(Zecca et al. 2004), which is normally associated to
changes in iron metabolism and/or homeostasis. Iron
accumulation affects protein modification, misfolding, and
aggregation (Hashimoto et al. 1999a, b; Uversky et al.
2001). Besides, it has an important effect on production of
radical species and eventually OS (Uversky et al. 2001;
Zecca et al. 2004; Hirose et al. 2003).
In AD it was observed that iron accumulates in the same
brain regions that are characterized by amyloid-b (Ab)
deposition, such as hippocampus, parietal cortex, and
motor cortex (Good et al. 1992; Dedman et al. 1992;
Connor et al. 1992b; LeVine 1997). In addition, iron
accumulation was also observed in neurons with neurofi-
brillary tangles (NFT) (Smith et al. 1997). Recently,
increased iron both in cortex and in cerebellum of pre-
clinical AD/mild cognitive impaired (MCI) cases was
found (Smith et al. 2010). Interestingly, binding of ferric
iron to the tau protein precedes the aggregation of hyper-
phosphorylated tau and the subsequent formation of NFT
(Yamamoto et al. 2002). Ab is a metalloprotein that binds
transition metal ions through three histidine residues
located in the N-terminal domain (Nakamura et al. 2007;
Atwood et al. 2000). Metal binding remotes Ab aggrega-
tion (Bush 2003; House et al. 2004; Loske et al. 2000) and
in the absence of metal ions Ab is unable to aggregate
(Barrow et al. 1992; Faller 2009). A second link between
iron homeostasis and AD is based on the observation that
AbPP expression is iron regulated; AbPP levels increase
upon iron treatment and decrease upon addition of an iron
chelator in neuroblastoma cells (Rogers et al. 2002).
Interestingly, disease progression of T2DM correlates with
amylin deposition, which, similar to Ab and tau, undergoes
a change in tertiary structure and is finally deposited in
insulin-producing pancreatic islet b-cells (Hoppener et al.
2000). Amylin is also known as islet amyloid polypeptide
(IAPP). In a recent study, human amylin induced signifi-
cant increase in producing ROS via inhibition of mito-
chondrial complex IV similarly to Ab (Lim et al. 2010).
Accumulating evidence suggests that iron plays a
pathogenic role in T2DM and its complications, such as
microangiopathy and atherosclerosis (Swaminathan et al.
2007; Rajpathak et al. 2009). In addition to the induction of
OS, iron may also impede insulin extraction in the liver,
impair pancreatic insulin secretion, and interfere with
insulin action and glucose uptake in adipocytes. Of note, a
reduction in iron overload with either phlebotomy or iron
chelation therapy has been shown to reverse or improve
glycemic control in T2DM (Swaminathan et al. 2007).
Experimental studies have indicated that iron deficiency is
related to increased insulin sensitivity in animals (Borel
et al. 1993; Farrell et al. 1988), while epidemiological
studies have reported an association between iron overload
and peripheral insulin resistance (Dandona et al. 1983).
Interestingly, elevated body iron stores were recently
suggested to be a component of the MetS (Fernandez-Real
et al. 1999).
Transferrin and ferritin in AD and T2DM
Transferrin (for iron mobilization) and ferritin (for iron
storage) are well-known proteins involved in iron transport
and storage. Transferrin accounts for approximately 0.4%
of the total protein in the brain (Connor et al. 1992b) and is
found predominantly in white matter or areas high in white
matter (Connor et al. 1987, 1992b). At the cellular level,
transferrin is localized mainly in oligodendrocytes (Connor
et al. 1990) although neuronal immunostaining has also
been reported (Oh et al. 1986). Ferritin levels in the human
brain are 10 times higher than transferrin (Connor et al.
1992b). Connor et al. (1992a) demonstrated in AD human
brains that transferrin and ferritin in general are found
predominantly in oligodendrocytes. Transferrin is homog-
enously distributed around the senile plaques and is
apparently extracellular. In addition, transferrin is found in
astrocytes in the cerebral cortical white matter of the
Alzheimer’s tissue rather than its normal distribution in
oligodendrocytes. A robust ferritin immunoreaction
accompanies senile plaques and many blood vessels in the
Alzheimer’s brain tissue. Although many ferritin-positive
oligodendrocytes are present in the Alzheimer’s tissue,
most of the ferritin-containing cells associated with senile
plaques and blood vessels are microglia (Connor et al.
1992a).
Alterations in ferritin or transferrin are also reported for
T2DM. For example, in a cross-sectional study of Finnish
men, it was reported that men with the highest quintile of
ferritin had 21.6% higher levels of insulin and 6.1% higher
levels of glucose (Tuomainen et al. 1997). Other investi-
gators reported that the association of ferritin with insulin
sensitivity (assessed by hyperinsulinemic euglycemic
clamp) was independent of body mass index (BMI) and
other relevant factors (Fernandez-Real et al. 1998, 2007).
Similarly, several other cross-sectional studies have also
reported an inverse correlation between serum ferritin
levels and measures of insulin sensitivity (Fernandez-Real
et al. 2007; Haap et al. 2003). In addition to the potential
effect of iron on insulin action, insulin may also affect iron
metabolism. In vitro data suggest that insulin is capable of
redistributing transferrin receptor to the cell surface leading
to increased cellular iron uptake in adipose tissue and the
liver (Davis et al. 1986; Tanner and Lienhard 1987). This
effect of insulin on the up-regulation of iron uptake occurs
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concurrently with its effect on glucose uptake (Tanner and
Lienhard 1989). This finding has been further substantiated
by experiments in rats which have shown that insulin
injection leads to increased serum levels of soluble trans-
ferrin receptor (Clairmont and Czech 1990). Thus, hyper-
insulinemia in states of insulin resistance may contribute to
high circulating soluble transferrin receptor levels. This
hypothesis is supported by a recent study among Caucasian
men in which a significant inverse correlation between
soluble transferrin receptor levels and insulin sensitivity
was reported (Fernandez-Real et al. 2007). Moreover,
increasing evidence suggests that serum ferritin, a good
indicator of body iron stores, is positively associated with
MetS (Jehn et al. 2004; Choi et al. 2005).
Metallothionein in AD and T2DM
Metallothionein (MT) research in the brain has shown that
this family of proteins plays a major role in brain physi-
ology (Hidalgo et al. 2001). There are four closely linked
MT genes (MT-I-IV) present in rodents (Quaife et al. 1994;
Palmiter et al. 1992). Metallothionein-I and metallothio-
nein-II (MT-I&II) are expressed coordinately in most tis-
sues including those of the CNS (Campagne et al. 2000),
while metallothionein-III (MT-III) and metallothionein-IV
(MT-IV) show a much more restricted tissue expression
(primarily localized in the CNS and stratified squamous
epithelia, respectively). There is compelling evidence that
MT-I&II are involved in the response of the brain to
damage (Hidalgo et al. 2001), and indeed there is a sig-
nificant up-regulation of MT-I/MT-II proteins in a number
of human neurological diseases, including AD (Chuah and
Getchell 1999; Adlard et al. 1998; Zambenedetti et al.
1998; Hidalgo et al. 2006), while MT-III seems to decrease
in AD subjects (Yu et al. 2001).
In T2DM, MT was found to protect islets b-cells from
most kinds of ROS (Li et al. 2004a, b).
Heme oxygenase-1 in AD and T2DM
Heme oxygenases localize within the endoplasmatic
reticulum where they function, in association with NADPH
cytochrome P450 reductase, to oxidize heme to biliverdin,
free ferrous iron, and carbon monoxide (CO). Two iso-
forms of heme oxygenase, HO-1 and HO-2, exist in
mammals. HO-1 expresses in the brain in few neurons and
neuroglia (Baranano and Snyder 2001). It was shown that
HO-1 induction, as consequence of OS, may protect cells
by enhancing the breakdown of pro-oxidant heme to the
radical-scavenging bile pigments, biliverdin, and bilirubin
(Baranano and Snyder 2001; Nakagami et al. 1993; Dore
et al. 1999). In AD brain, HO-1 protein co-localizes to
astrocytes, neurons, NFT, senile plaques, corpora amyla-
cea, ependymocytes, choroid plexus epithelial cells, and
some endothelial and vascular smooth muscle cells (Smith
et al. 1994a; Schipper et al. 1995). In AD hippocampus an
increased immunoreactive HO-1 in astrocytes was found
(Schipper et al. 1995). Even in postmortem brain samples
of MCI, HO-1 was found to increase (Schipper et al. 2006).
In T2DM it was demonstrated in mononuclear cells, that
the HO-1 gene expression was significantly higher in
patients compared to controls (Avogaro et al. 2003).
Additionally, these authors demonstrated reduction of
HO-1 expression after metabolic normalization in some of
the patients (Avogaro et al. 2003).
Animal model
Streptozotocin (STZ) is a naturally produced antibiotic
from Streptomyces achromogenes, which is widely used to
induce experimental diabetes in mice. Its biological effect
lies in the susceptibility of pancreas islets to the drug,
which enters the cytoplasm via the glucose transporter
GLUT2 (Wang and Gleichmann 1998; Schnedl et al.
1994). Several deleterious effects of STZ have been
reported including DNA methylation (Murata et al. 1999),
protein modification (Bidasee et al. 2003), and ROS gen-
eration (Chen et al. 2001; Gille et al. 2002). It was found
that treating STZ-diabetic mice with ZnSO4 significantly
up-regulated MT production in pancreatic islets, which in
parallel prevented tissue degeneration and STZ-diabetes
induction (Ohly et al. 2000). The protective role of MT is
also demonstrated by the reduction of STZ-induced DNA
damage, degranulation and cell death of pancreatic b-cells
in transgenic mice over-expressing MT-1 upon STZ treat-
ment (Chen et al. 2001). In a recent study, it was reported
that treatment of STZ-diabetic mice with Zn reversed the
increased levels of iron and MT caused by STZ in the
periphery (e.g. urine, liver, pancreas, and kidney) as well as
in the CNS (cerebellum and midbrain) (Beltramini et al.
2006). These authors found again a protective effect of Zn
that was demonstrated both in the periphery as well as in
the CNS. In STZ-induced T2DM rats, it was shown that
caloric restriction could significantly reduce triglyceride,
ROS, and inflammation in the brain (Ugochukwu et al.
2006). The antioxidant enzyme, glutathione peroxidase
was reduced as consequence of diabetes induction, while
caloric restriction reversed this effect (Ugochukwu et al.
2006).
Considering the presence of insulin and insulin-receptors
in the brain, an experimental rat model was developed by
using intracerebroventricular (icv) STZ to induce the IRBS
(Hoyer et al. 1994). This was found to cause prolonged
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impairment of brain glucose and energy metabolism,
decreased choline acetyltransferase levels in the hippo-
campus as well as impairment in learning and memory
(Lannert and Hoyer 1998; Zeevalk et al. 1998; Hoyer et al.
1999, 2000; Hoyer and Lannert 1999; Hoyer 1997). In the
last decade, this model was extensively investigated at
molecular, pathological, and neurochemical levels and it is
notable that many features of this model resemble alterations
occurring in AD (de la Monte and Wands 2008; Salkovic-
Petrisic and Hoyer 2007; Gru¨nblatt et al. 2004, 2006, 2007;
Salkovic-Petrisic et al. 2006; Moreira et al. 2004; Shoham
et al. 2003, Salkovic-Petrisic and Lackovic 2003, Plaschke
et al. 2010; de la Monte and Tong 2009; Tong et al. 2009).
Interestingly, it was found that STZ-icv causes decrease of
MT-I&II gene expression in the cortex and striatum, while
increase in the cerebellum which might indicate specific
sensitivity of cortex and putamen to OS (Gru¨nblatt et al.
2006). Another indication of OS in STZ-icv rats is the
findings of significant elevations of malondialdehyde levels
and decreased glutathione levels in various brain regions
(Sharma and Gupta 2001, 2002; Ishrat et al. 2009).
In an obesity/T2DM mouse model, using high fat diet,
Moroz et al. demonstrated a link between AD and T2DM
showing that both present insulin resistance in the brain,
but still where not fully similar to the neuropathology in
AD (Moroz et al. 2008).
In another mice model for T2DM (db/db CBL57) it was
found that anti-oxidative defence enzymes, such as super-
oxide dismutase, catalase, and glutathione-S-transferase
were significantly lower in the brains than in control ani-
mals (Makar et al. 1995). In addition, the amount of
polyunsaturated fatty acids was increased in brains of these
animals (Makar et al. 1995). These facts point to the sus-
ceptibility of these diabetic mice to OS and ROS not only
in the periphery, but also in the brain.
Another link between AD pathology and diabetes is the
ferric nitrilotriacetate (Fe-NTA)-induced diabetes in rats.
(Fe-NTA), an iron chelate, induces carcinoma in the kid-
neys after intermittent injection and causes diabetes, one of
the symptoms of hemochromatosis (Li et al. 1987; Awai
et al. 1979). A unique characteristic of Fe-NTA is that it
generates free radicals without reducing ferric to ferrous
iron (Kawabata et al. 1986), while reduction with H2O2
induces hydroxyl radicals in a Fenton reaction. In addition,
Fe-NTA causes rapid increase in free iron and a higher
content in the serum compared with other iron chelates
(Liu et al. 1991). Using this model, it was found that iron
was accumulating in the cortex and the hypothalamus,
rather than in other areas of the brain (Nakatsuka et al.
2009). HO-1 was induced both in the cortex and in the
hypothalamus, while muscarinic acetylcholine receptor
mRNAs were suppressed in the cortex (Nakatsuka et al.
2009).
Conclusion
From the current literature, it becomes clear that iron
involvement both in AD and in T2DM is common and
causes degeneration of either neurons of islet b-cells in the
pancreas. It is probably not far fetched to hypothesize that
MetS causing insulin resistance leads to increase in iron
stores in the pancreas as well as in sensitive brain regions
which then further may induce T2DM and AD (for the
communalities see Fig. 1). The mechanisms of action,
which then cause aggregation of amyloid plaques or amylin
are strikingly similar in which both cause further toxicity in
the cells. Still, the brains of T2DM were very scarcely
investigated for OS markers including iron, HO-1, or MT;
therefore, it would be of interest linking these alterations
known to be involved in AD to T2DM. To do this, further
experimental work is essential.
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